Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market By Infection (Cellulitis, Abscess, Surgical Wounds, & Traumatic Wound), By Type Of Drug (Delafloxacin, Vancomycin, Ceftaroline Fosamil, Telvancin & Others), By Pathogens (MSSA, MRSA, Beta-Hemolytic Streptococcus, Escherichia Coli & Others) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

The report titled “Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall ABSSSI treatment market along with the market size and estimates for the duration 2015 to 2025. The said research study cover in-depth analysis of multiple market segments based on type of infection, pathogen, drug, and different geographies. According to market experts acute skin and skin structure infections (ABSSSI) comprise set of bacterial infections that involve multiple layers of the skin and associated tissues. These infections tend to be more severe in nature than simple infections of the skin, and they usually require systemic antibacterial therapy and patient hospitalization. The majority of ABSSSIs are caused by Gram-positive bacterial strains, especially Staphylococcus aureus. However, Gram-negative bacteria has high importance in specific types of infections, as well as in hospital settings.

For the purpose of this study, the global ABSSSI treatment market is segmented on the basis of drugs type into Delafloxacin, Vancomycin, Ceftaroline fosamil, Telvancin, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, TMP-SMZ, and Others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The global ABSSSI treatment market is also segmented on the basis of type of infections into cellulitis, abscess/boil/cyst, surgical wound, and traumatic wound. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The global ABSSSI treatment market is segmented on the basis of type of pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, Pseudomonas aeruginosa, and Others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

The geographical segmentation of ABSSSI treatment market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.

The ABSSSI treatment market is observed as the most diversified and competitive market comprising large number of players.  The market is dominated by several players, depending on their major competencies. The key players in this market are Furiex Pharmaceuticals, Inc., GlaxoSmithKline plc, Melinta Therapeutics, Inc, Debiopharm International S.A., MerLion Pharmaceuticals Pte Ltd., Durata Therapeutics, Inc., Paratek Pharmaceuticals, Inc. and Cempra, Inc. among others.

Based on the type of pathogen, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

  • Methicillin sensitive Staphylococcus aureus (MSSA)
  • Methicillin resistant Staphylococcus aureus (MRSA)
  • Beta-hemolytic Streptococcus
  • Escherichia coli
  • Enterococcus faecalis
  • Pseudomonas aeruginosa
  • Others

Acute Skin & Skin Structure Bacterial Infection (ABSSSI) Treatment Market

In year 2016, MSSA and MRSA accounted for more than 50% of the market share due to key drivers such as rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital acquired infections, and incessant research and development in field of ABSSSI treatment. According to American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Thus, prevalence of hospital-acquired infections are increasing coupled with stringent regulations & policies adopted by government bodies against hospitals who lack in maintain sterile environment.

Based on the type of pathogen, the global acute bacterial skin and skin structure infections treatment market is segmented as follows:

  • Methicillin sensitive Staphylococcus aureus (MSSA)
  • Methicillin resistant Staphylococcus aureus (MRSA)
  • Beta-hemolytic Streptococcus
  • Escherichia coli
  • Enterococcus faecalis
  • Pseudomonas aeruginosa
  • Others

In year 2016, MSSA and MRSA accounted for more than 50% of the market share due to key drivers such as rising prevalence of multi-resistance bacterial infections, high public awareness associated with hospital acquired infections, and incessant research and development in field of ABSSSI treatment. According to American Pharmacists Association, approximately 3 million patients hospitalized each year in the U.S. with ABSSSI often present treatment challenges owing to their underlying medical conditions, making optimal antibiotic selection difficult. Thus, prevalence of hospital-acquired infections are increasing coupled with stringent regulations & policies adopted by government bodies against hospitals who lack in maintain sterile environment.

Acute Skin & Skin Structure Bacterial Infection (ABSSSI) Treatment Market

Choose License Type
Published Date:  Aug 2017
Category:  Pharmaceuticals
Report ID:   58628
Report Format:   PDF
Pages:   120
Rating:    4.3 (65)
Connect With Us
+1-408-641-3282
24/7 Research Support